Third Quarter 2023 Financial Supplement
Quarterly Financial Supplement
This document is dated
not be accurate after such date and
|
|
|
|
Table of Contents |
|
Financial Highlights |
|
Consolidated Income Statements |
|
|
|
Corporate and Other Operations Analysis |
9 |
Consolidated Balance Sheets |
10 |
Condensed Consolidated Statements of Cash Flows |
11 |
BASIS OF PRESENTATION: |
|
All dollar amounts are in millions, unless otherwise noted. |
Adjusted income (loss) from operations is a principal financial measure of profitability used by
Adjusted revenues is used by
Effective
In some financial tables in this Quarterly Financial Supplement, we present percentage changes. When those changes are so large as to become not meaningful, we present "N/M" in place of the computed percentage.
Financial Highlights (unaudited)
(Dollars in millions, except per share amounts) |
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
2023 |
2022 (1) |
% Change |
2023 |
2022 (1) |
% Change |
|||||||||||||||||
Total revenues |
$ |
49,048 |
$ |
45,281 |
8 |
% |
$ |
144,151 |
$ |
134,765 |
7 |
% |
||||||||||
Net realized investment results from certain equity method |
30 |
80 |
(63) |
22 |
134 |
(84) |
||||||||||||||||
investments |
||||||||||||||||||||||
Adjusted revenues |
$ |
49,078 |
$ |
45,361 |
8 |
% |
$ |
144,173 |
$ |
134,899 |
7 |
% |
||||||||||
Shareholders' net income |
$ |
1,408 |
$ |
2,757 |
(49) % |
$ |
4,135 |
$ |
5,511 |
(25) |
% |
|||||||||||
Pre-Tax Adjusted Income (Loss) From Operations by Segment |
||||||||||||||||||||||
|
$ |
1,716 |
$ |
1,625 |
6 |
% |
$ |
4,552 |
$ |
4,402 |
3 |
% |
||||||||||
|
1,222 |
1,050 |
16 |
3,509 |
3,582 |
(2) |
||||||||||||||||
Corporate and Other Operations |
(409) |
(295) |
(39) |
(1,202) |
(582) |
(107) |
||||||||||||||||
Consolidated pre-tax adjusted income from operations |
$ |
2,529 |
$ |
2,380 |
6 |
% |
$ |
6,859 |
$ |
7,402 |
(7) |
% |
||||||||||
Adjusted income tax expense |
518 |
521 |
(1) |
1,410 |
1,622 |
(13) |
||||||||||||||||
Consolidated after-tax adjusted income from operations |
$ |
2,011 |
$ |
1,859 |
8 |
% |
$ |
5,449 |
$ |
5,780 |
(6) |
% |
||||||||||
Adjusted EBITDA (2) |
$ |
3,206 |
$ |
2,950 |
9 |
% |
$ |
8,847 |
$ |
9,089 |
(3) |
% |
||||||||||
Operating cash flow (see page 11) |
$ |
2,826 |
$ |
3,283 |
(14) % |
$ |
10,346 |
$ |
6,557 |
58 |
% |
|||||||||||
SG&A expense ratio (3) |
7.7 |
% |
7.0 |
% |
(70) bps |
7.5 |
% |
7.2 |
% |
(30) |
bps |
|||||||||||
Adjusted SG&A expense ratio (3) |
7.3 |
% |
6.9 |
% |
(40) bps |
7.3 |
% |
7.1 |
% |
(20) |
bps |
|||||||||||
Weighted average shares (in thousands) |
297,131 |
307,517 |
297,663 |
315,647 |
||||||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||||
2023 |
2022 (1) |
% Change |
2023 |
2022 (1) |
% Change |
|||||||||||||||||
Pre-tax |
After-tax |
Pre-tax |
After-tax |
Pre-tax |
After-tax |
Pre-tax |
After-tax |
|||||||||||||||
Diluted earnings per share |
||||||||||||||||||||||
Shareholders' net income |
$ |
4.74 |
$ |
8.97 |
(47) % |
$ |
13.89 |
$ |
17.46 |
(20) |
% |
|||||||||||
Adjustments to reconcile to adjusted income from operations |
||||||||||||||||||||||
Net realized investment losses (4) |
$ |
0.15 |
0.14 |
$ |
0.53 |
0.48 |
$ |
0.22 |
0.19 |
$ |
1.99 |
1.62 |
||||||||||
Amortization of acquired intangible assets |
1.53 |
1.22 |
1.50 |
1.05 |
4.60 |
3.54 |
4.50 |
3.36 |
||||||||||||||
Special items |
||||||||||||||||||||||
Charges (benefits) associated with litigation matters |
0.68 |
0.58 |
- |
- |
0.67 |
0.58 |
(0.09) |
(0.06) |
||||||||||||||
Loss (gain) on sale of businesses |
0.07 |
0.06 |
(5.64) |
(4.52) |
0.07 |
0.06 |
(5.49) |
(4.39) |
||||||||||||||
Integration and transaction-related costs |
0.04 |
0.03 |
0.08 |
0.07 |
0.07 |
0.05 |
0.35 |
0.27 |
||||||||||||||
Charge for organizational efficiency plan |
- |
- |
- |
- |
- |
- |
0.07 |
0.05 |
||||||||||||||
Total special items |
$ |
0.79 |
0.67 |
$ |
(5.56) |
(4.45) |
$ |
0.81 |
0.69 |
$ |
(5.16) |
(4.13) |
||||||||||
Adjusted income from operations |
$ |
6.77 |
$ |
6.05 |
12 |
% |
$ |
18.31 |
$ |
18.31 |
- |
% |
||||||||||
CUSTOMER RELATIONSHIPS |
As of |
As of |
||||||||||||||||||||
(Relationships and lives in thousands) |
2023 |
2022 |
% Change |
2022 |
% Change |
|||||||||||||||||
Pharmacy (5) |
98,325 |
94,846 |
4 |
% |
93,905 |
5 % |
||||||||||||||||
Medical (see page 7) |
19,607 |
17,954 |
9 |
18,004 |
9 |
|||||||||||||||||
Behavioral Care (6) |
25,100 |
44,522 |
(44) |
44,841 |
(44) |
|||||||||||||||||
Dental |
18,593 |
18,380 |
1 |
18,397 |
1 |
|||||||||||||||||
Medicare Part D |
2,544 |
2,902 |
(12) |
2,874 |
(11) |
|||||||||||||||||
Total customer relationships (5) (6) |
164,169 |
178,604 |
(8) % |
178,021 |
(8) % |
- Effective
January 1, 2023 , the Company adopted ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts, and related amendments. Prior year results have been restated to reflect the adoption of the new accounting guidance. The cumulative effects of adopting the new standard were immaterial. Please refer to the Basis of Presentation section for additional details. - Adjusted income from operations excluding interest, taxes, depreciation and amortization ("Adjusted EBITDA") is a non-GAAP measure, defined as shareholders' net income excluding income taxes and the pre-tax impact of special items, interest expense, total depreciation and amortization, and net realized investment results.
- SG&A expense ratio is calculated as selling, general and administrative expenses including special items divided by total revenues. Adjusted SG&A expense ratio is calculated as selling, general and administrative expenses excluding special items divided by adjusted revenues.
- Includes the Company's share of certain realized investment results of its joint ventures reported in the
Cigna Healthcare segment using the equity method of accounting. - Effective
January 1, 2023 , Pharmacy customers and total customer relationships have been updated to reflect customer filled prescriptions through Inside Rx. Previously these customers had been estimated based on active customers over a period of time. Pharmacy customers and total customer relationships for prior periods have been restated to reflect this change. - Behavioral care and total customer relationships as of
September 30, 2023 were impacted by the non-renewal of a supplemental behavioral coverage contract withNew York Life which was insignificant to Total revenues, Shareholders' net income and Adjusted income from operations. Behavioral care and total customer relationships as ofDecember 31, 2022 excluding the impact of the supplemental behavioral coverage contract withNew York Life were 24,696 and 157,876, respectively.
1
Consolidated Income Statements (unaudited)
(Dollars in millions) |
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
2023 |
2022 (1) |
% Change |
2023 |
2022 (1) |
% Change |
|||||||||||||||||
Revenues |
||||||||||||||||||||||
Pharmacy revenues |
$ |
34,531 |
$ |
32,762 |
5 |
% |
$ |
100,639 |
$ |
95,431 |
5 |
% |
||||||||||
Premiums |
10,998 |
9,586 |
15 |
33,062 |
30,368 |
9 |
||||||||||||||||
Fees and other revenues |
3,198 |
2,729 |
17 |
9,574 |
8,023 |
19 |
||||||||||||||||
Net investment income |
321 |
204 |
57 |
876 |
943 |
(7) |
||||||||||||||||
Total revenues |
49,048 |
45,281 |
8 |
144,151 |
134,765 |
7 |
||||||||||||||||
Benefits and expenses |
||||||||||||||||||||||
Pharmacy and other service costs |
33,639 |
31,777 |
6 |
98,540 |
92,740 |
6 |
||||||||||||||||
Medical costs and other benefit expenses |
8,927 |
7,751 |
15 |
27,007 |
24,215 |
12 |
||||||||||||||||
Selling, general and administrative expenses excluding special items |
3,574 |
3,127 |
14 |
10,539 |
9,584 |
10 |
||||||||||||||||
Amortization of acquired intangible assets |
454 |
460 |
(1) |
1,368 |
1,419 |
(4) |
||||||||||||||||
Special items |
214 |
24 |
N/M |
221 |
106 |
108 |
||||||||||||||||
Total benefits and expenses |
46,808 |
43,139 |
9 |
137,675 |
128,064 |
8 |
||||||||||||||||
Income from operations |
2,240 |
2,142 |
5 |
6,476 |
6,701 |
(3) |
||||||||||||||||
Interest expense and other |
(365) |
(304) |
(20) |
(1,086) |
(904) |
(20) |
||||||||||||||||
(Loss) gain on sale of businesses |
(21) |
1,735 |
N/M |
(21) |
1,735 |
N/M |
||||||||||||||||
Net realized investment losses |
(14) |
(82) |
83 |
(44) |
(493) |
91 |
||||||||||||||||
Income before income taxes |
1,840 |
3,491 |
(47) |
5,325 |
7,039 |
(24) |
||||||||||||||||
Total income taxes |
391 |
713 |
(45) |
1,060 |
1,479 |
(28) |
||||||||||||||||
Net income |
1,449 |
2,778 |
(48) |
4,265 |
5,560 |
(23) |
||||||||||||||||
Less: Net income attributable to noncontrolling interests |
41 |
21 |
95 |
130 |
49 |
165 |
||||||||||||||||
Shareholders' net income |
$ |
1,408 |
$ |
2,757 |
(49) % |
$ |
4,135 |
$ |
5,511 |
(25) % |
||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||||
2023 |
2022 (1) |
2023 |
2022 (1) |
|||||||||||||||||||
Pre-tax |
After-tax |
Pre-tax |
After-tax |
% Change |
Pre-tax |
After-tax |
Pre-tax |
After-tax |
% Change |
|||||||||||||
Shareholders' net income |
$ |
1,408 |
$ |
2,757 |
(49) % |
$ |
4,135 |
$ |
5,511 |
(25) % |
||||||||||||
Adjustments to reconcile adjusted income from operations |
||||||||||||||||||||||
Net realized investment losses (2) |
$ |
44 |
41 |
$ |
162 |
145 |
$ |
66 |
56 |
$ |
627 |
513 |
||||||||||
Amortization of acquired intangible assets |
454 |
363 |
460 |
322 |
1,368 |
1,053 |
1,419 |
1,061 |
||||||||||||||
Special items |
||||||||||||||||||||||
Charges (benefits) associated with litigation matters |
201 |
171 |
- |
- |
201 |
171 |
(28) |
(20) |
||||||||||||||
Loss (gain) on sale of businesses |
21 |
19 |
(1,735) |
(1,388) |
21 |
19 |
(1,735) |
(1,388) |
||||||||||||||
Integration and transaction-related costs |
13 |
9 |
24 |
23 |
20 |
15 |
112 |
86 |
||||||||||||||
Charge for organizational efficiency plan |
- |
- |
- |
- |
- |
- |
22 |
17 |
||||||||||||||
Adjusted income from operations |
$ |
2,011 |
$ |
1,859 |
8 |
% |
$ |
5,449 |
$ |
5,780 |
(6) % |
- Effective
January 1, 2023 , the Company adopted ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts, and related amendments. Prior year results have been restated to reflect the adoption of the new accounting guidance. The cumulative effects of adopting the new standard were immaterial. Please refer to the Basis of Presentation section for additional details. - Includes the Company's share of certain realized investment results of its joint ventures reported in the
Cigna Healthcare segment using the equity method of accounting.
2
Segment Results (unaudited)
(Dollars in millions) |
Three Months Ended |
Nine Months Ended |
||||||||||||||
2023 |
2022 |
% Change |
2023 |
2022 |
% Change |
|||||||||||
Revenues |
||||||||||||||||
Pharmacy revenues |
$ |
35,640 |
$ |
33,796 |
5 |
% |
$ |
104,529 |
$ |
98,780 |
6 |
% |
||||
Fees and other revenues |
2,893 |
1,877 |
54 |
8,276 |
5,316 |
56 |
||||||||||
Net investment income |
63 |
25 |
152 |
175 |
51 |
243 |
||||||||||
Total revenues (1) |
38,596 |
35,698 |
8 |
112,980 |
104,147 |
8 |
||||||||||
Benefits and expenses |
||||||||||||||||
Pharmacy and other service costs |
36,000 |
33,338 |
8 |
105,819 |
97,625 |
8 |
||||||||||
Gross profit |
2,596 |
2,360 |
10 |
7,161 |
6,522 |
10 |
||||||||||
Selling, general and administrative expenses excluding special items |
837 |
718 |
17 |
2,468 |
2,078 |
19 |
||||||||||
Amortization of acquired intangible assets |
443 |
442 |
- |
1,330 |
1,329 |
- |
||||||||||
Special items |
44 |
- |
N/M |
44 |
- |
N/M |
||||||||||
Income from operations |
1,272 |
1,200 |
6 |
3,319 |
3,115 |
7 |
||||||||||
Interest expense and other |
1 |
- |
N/M |
(1) |
(1) |
- |
||||||||||
Net realized investment (losses) |
(1) |
- |
N/M |
- |
- |
N/M |
||||||||||
Income before income taxes |
1,272 |
1,200 |
6 |
3,318 |
3,114 |
7 |
||||||||||
Pre-tax adjustments required to reconcile to adjusted income from operations |
||||||||||||||||
Pre-tax (income) attributable to noncontrolling interests |
(44) |
(17) |
(140) |
(41) |
||||||||||||
Net realized investment losses |
1 |
- |
- |
- |
||||||||||||
Amortization of acquired intangible assets |
443 |
442 |
1,330 |
1,329 |
||||||||||||
Special items |
44 |
- |
44 |
- |
||||||||||||
Pre-tax adjusted income from operations |
$ |
1,716 |
$ |
1,625 |
6 |
% |
$ |
4,552 |
$ |
4,402 |
3 |
% |
||||
Pre-tax adjusted margin |
4.4 |
% |
4.6 |
% |
(20) bps |
4.0 |
% |
4.2 % |
(20) bps |
- Total revenues equal adjusted revenues as there were no special items in the periods presented.
3
Key Metrics (unaudited)
(Dollars and adjusted scripts in millions) |
Three Months Ended |
Nine Months Ended |
||||||||||||||
2023 |
2022 |
% Change |
2023 |
2022 |
% Change |
|||||||||||
Selected Financial Information |
||||||||||||||||
Adjusted EBITDA (1) |
$ |
1,887 |
$ |
1,758 |
7 |
% |
$ |
5,033 |
$ |
4,776 |
5 |
% |
||||
Pharmacy revenue by distribution channel |
||||||||||||||||
Network revenues |
$ |
16,926 |
$ |
16,583 |
2 |
% |
$ |
49,080 |
$ |
48,221 |
2 |
% |
||||
Home delivery and specialty revenues |
16,324 |
15,583 |
5 |
48,943 |
45,550 |
7 |
||||||||||
Other revenues |
2,390 |
1,630 |
47 |
6,506 |
5,009 |
30 |
||||||||||
Total pharmacy revenues |
$ |
35,640 |
$ |
33,796 |
5 |
% |
$ |
104,529 |
$ |
98,780 |
6 |
% |
||||
Pharmacy script volume |
||||||||||||||||
Adjusted network scripts (2) |
331 |
325 |
2 |
% |
978 |
963 |
2 |
% |
||||||||
Adjusted home delivery and specialty scripts (2) |
63 |
71 |
(11) |
193 |
210 |
(8) |
||||||||||
Total adjusted scripts (2) |
394 |
396 |
(1) % |
1,171 |
1,173 |
- |
% |
|||||||||
Generic fill rate |
||||||||||||||||
Network |
86.8 |
% |
86.6 |
% |
20 |
bps |
87.7 |
% |
87.1 |
% |
60 |
bps |
||||
Home delivery |
85.9 |
% |
84.7 |
% |
120 |
bps |
85.1 |
% |
85.3 |
% |
(20) |
bps |
||||
Overall generic fill rate |
86.7 |
% |
86.4 |
% |
30 |
bps |
87.5 |
% |
87.0 |
% |
50 |
bps |
- Adjusted EBITDA is defined as
Evernorth Health Services segment pre-tax adjusted income from operations excluding interest expense and depreciation and amortization, net of amortization of acquired intangible assets that is already excluded in segment pre-tax adjusted income from operations. - Non-specialtynetwork scripts filled through 90-day programs, and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.
4
Segment Results (unaudited)
(Dollars in millions) |
Three Months Ended |
Nine Months Ended |
||||||||||||||
2023 |
2022 (1) |
% Change |
2023 |
2022 (1) |
% Change |
|||||||||||
Revenues |
||||||||||||||||
Premiums |
$ |
10,911 |
$ |
9,508 |
15 |
% |
$ |
32,786 |
$ |
28,649 |
14 |
% |
||||
Fees and other revenues |
1,651 |
1,488 |
11 |
4,938 |
4,577 |
8 |
||||||||||
Net investment income |
176 |
101 |
74 |
454 |
545 |
(17) |
||||||||||
Total revenues |
12,738 |
11,097 |
15 |
38,178 |
33,771 |
13 |
||||||||||
Benefits and expenses |
||||||||||||||||
Medical costs |
8,786 |
7,681 |
14 |
26,554 |
23,203 |
14 |
||||||||||
Selling, general and administrative expenses excluding special items |
2,763 |
2,449 |
13 |
8,141 |
7,126 |
14 |
||||||||||
Amortization of acquired intangible assets |
11 |
17 |
(35) |
38 |
89 |
(57) |
||||||||||
Special items |
157 |
- |
N/M |
157 |
- |
N/M |
||||||||||
Total benefits and expenses |
11,717 |
10,147 |
15 |
34,890 |
30,418 |
15 |
||||||||||
Income from operations |
1,021 |
950 |
7 |
3,288 |
3,353 |
(2) |
||||||||||
Interest expense and other |
3 |
4 |
(25) |
6 |
8 |
(25) |
||||||||||
Net realized investment (losses) |
(5) |
(78) |
94 |
(42) |
(408) |
90 |
||||||||||
Income before income taxes |
1,019 |
876 |
16 |
3,252 |
2,953 |
10 |
||||||||||
Pre-tax adjustments required to reconcile to adjusted income from operations |
||||||||||||||||
Pre-tax (income) attributable to noncontrolling interests |
- |
(1) |
(2) |
(2) |
||||||||||||
Net realized investment losses (2) |
35 |
158 |
64 |
542 |
||||||||||||
Amortization of acquired intangible assets |
11 |
17 |
38 |
89 |
||||||||||||
Special items |
157 |
- |
157 |
- |
||||||||||||
Pre-tax adjusted income from operations |
$ |
1,222 |
$ |
1,050 |
16 |
% |
$ |
3,509 |
$ |
3,582 |
(2) % |
|||||
Pre-tax adjusted margin |
9.6 |
% |
9.4 |
% |
20 |
bps |
9.2 |
% |
10.6 |
% |
(140) bps |
|||||
Reconciliation of total revenues to adjusted revenues |
||||||||||||||||
Total revenues |
$ |
12,738 |
$ |
11,097 |
15 |
% |
$ |
38,178 |
$ |
33,771 |
13 |
% |
||||
Net realized investment results from certain equity method investments |
30 |
80 |
(63) |
22 |
134 |
(84) |
||||||||||
Adjusted revenues |
$ |
12,768 |
$ |
11,177 |
14 |
% |
$ |
38,200 |
$ |
33,905 |
13 |
% |
- Effective
January 1, 2023 , the Company adopted ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts, and related amendments. Prior year results have been restated to reflect the adoption of the new accounting guidance. The cumulative effects of adopting the new standard were immaterial. Please refer to the Basis of Presentation section for additional details. - Includes the Company's share of certain realized investment results of its joint ventures reported in the
Cigna Healthcare segment using the equity method of accounting.
5
Premium Revenue and Medical Care Ratio (unaudited)
(Dollars in millions) |
Three Months Ended |
Nine Months Ended |
||||||||||||||||
2023 |
2022 |
% Change |
2023 |
2022 |
% Change |
|||||||||||||
Premiums: |
||||||||||||||||||
|
||||||||||||||||||
Insured |
$ |
4,144 |
$ |
3,821 |
8 |
% |
$ |
12,315 |
$ |
11,312 |
9 |
% |
||||||
Stop loss |
1,548 |
1,384 |
12 |
4,565 |
4,053 |
13 |
||||||||||||
Other |
362 |
353 |
3 |
1,095 |
1,065 |
3 |
||||||||||||
Total |
6,054 |
5,558 |
9 |
17,975 |
16,430 |
9 |
||||||||||||
|
||||||||||||||||||
Medicare Advantage |
2,189 |
1,949 |
12 |
6,605 |
6,080 |
9 |
||||||||||||
Medicare Part D |
224 |
240 |
(7) |
984 |
986 |
- |
||||||||||||
Other |
1,610 |
1,029 |
56 |
4,782 |
3,007 |
59 |
||||||||||||
Total |
4,023 |
3,218 |
25 |
12,371 |
10,073 |
23 |
||||||||||||
|
834 |
732 |
14 |
2,440 |
2,146 |
14 |
||||||||||||
Total premiums |
$ |
10,911 |
$ |
9,508 |
15 |
% |
$ |
32,786 |
$ |
28,649 |
14 |
% |
||||||
Medical Care Ratio |
80.5 |
% |
80.8 |
% |
30 |
bps |
81.0 |
% |
81.0 |
% |
- |
bps |
6
Total Medical Customers (unaudited)
COVERED LIVES BY |
As of |
As of |
COVERED LIVES BY |
As of |
As of |
||||||||||||
FUNDING TYPE: |
2023 |
2022 |
% Change |
2022 |
% Change |
MARKET SEGMENT: (4) |
2023 |
2022 (5) |
% Change |
2022 (5) |
% Change |
||||||
(Lives in thousands) |
(Lives in thousands) |
||||||||||||||||
Medical customers: (1) |
Medical customers: (1) |
||||||||||||||||
|
2,224 |
2,205 |
1 |
% |
2,238 |
(1) % |
National Accounts |
5,731 |
5,742 |
- |
% |
5,754 |
- |
% |
|||
|
Middle Market |
7,338 |
6,244 |
18 |
6,274 |
17 |
|||||||||||
Medicare Advantage |
599 |
541 |
11 |
529 |
13 |
Select |
2,871 |
2,721 |
6 |
2,760 |
4 |
||||||
Individual (2) |
898 |
348 |
158 |
337 |
166 |
Small |
69 |
54 |
28 |
64 |
8 |
||||||
Medicare Supplement and Other |
468 |
487 |
(4) |
483 |
(3) |
Total |
16,009 |
14,761 |
8 |
14,852 |
8 |
||||||
Total |
1,965 |
1,376 |
43 |
1,349 |
46 |
||||||||||||
|
1,198 |
1,179 |
2 |
1,169 |
2 |
|
1,970 |
1,381 |
43 |
1,354 |
45 |
||||||
|
13,785 |
12,556 |
10 |
12,614 |
9 |
|
1,628 |
1,812 |
(10) |
1,798 |
(9) |
||||||
|
5 |
5 |
- |
5 |
- |
||||||||||||
|
430 |
633 |
(32) |
629 |
(32) |
||||||||||||
Total medical customers |
19,607 |
17,954 |
9 |
% |
18,004 |
9 |
% |
Total medical customers |
19,607 |
17,954 |
9 |
% |
18,004 |
9 |
% |
- Includes individuals in our
Cigna Healthcare segment who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued byCigna Healthcare ; have access toCigna Healthcare's provider network for covered services under their medical plan; or have medical claims and services that are administered byCigna Healthcare . - As of
September 30, 2023 , individual business includes on-exchange Patient Protection and Affordable Care and Education Reconciliation Act ("ACA") business (884,000 customers) and off-exchange ACA business (14,000 customers). International Health excludes medical customers served by less than 100% owned subsidiaries, as well as certain customers served by our third-party administrator.International Health customers as ofSeptember 30, 2023 reflect the transition of certain runoff business to Other Operations beginningJanuary 1, 2023 .- Market Segments are defined as follows:
-
- the National Accounts market segment includes employers with 3,000 or more eligible employees;
- the Middle Market segment includes employers with 500 to 2,999 eligible employees, solutions for third party payers,
Taft Hartley plans, and other groups; - the Select market segment includes employers with 51 to 499 eligible employees;
- the Small market segment includes employers with 2 to 50 eligible employees;
- the
U.S. Government market segment offers Medicare Advantage (both to individuals who are post-65 retirees, as well as employer group sponsored pre- and post-65 retirees), Prescription Drug Program and Medicare Supplement as managed care alternatives to publicly funded health care programs. The segment also offers individual health insurance coverage both on and off the public exchanges. - the
International Health market segment is focused on health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.
- Prior year lives have been reclassified to reflect current market segment presentation at the employer level, according to the definitions discussed in note 4.
7
Unpaid Claims Liability (unaudited)
(Dollars in millions) |
Nine Months Ended |
Year Ended |
||||
2023 |
2022 |
|
||||
Beginning balance |
$ |
4,176 |
$ |
4,261 |
$ |
4,261 |
Less: Reinsurance and other amounts recoverable |
221 |
261 |
261 |
|||
Beginning balance, net |
3,955 |
4,000 |
4,000 |
|||
Incurred costs related to: |
||||||
Current year |
26,788 |
23,431 |
31,342 |
|||
Prior years |
(237) |
(278) |
(259) |
|||
Total incurred |
26,551 |
23,153 |
31,083 |
|||
Paid costs related to: |
||||||
Current year |
22,053 |
19,655 |
27,583 |
|||
Prior years |
3,362 |
3,450 |
3,545 |
|||
Total paid |
25,415 |
23,105 |
31,128 |
|||
Ending balance, net |
5,091 |
4,048 |
3,955 |
|||
Add: Reinsurance and other amounts recoverable |
226 |
202 |
221 |
|||
Ending balance (1) |
$ |
5,317 |
$ |
4,250 |
$ |
4,176 |
- The ending balance is included in the Insurance and contractholder liabilities balance on the Consolidated Balance Sheets. For additional information regarding this liability, see the Insurance and Contractholder Liabilities footnote in the Company's Form 10-Q for the period ended
September 30, 2023 , expected to be filed onNovember 2, 2023 .
8
Attachments
Disclaimer
Pediatrix Medical Group Reports Third Quarter Results
Third Quarter 2023 Press Release
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News